secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nemaura Medical Inc. (—)
CIK:        0001602078
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001079973-23-000236
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nemaura Medical restates Q1 and Q2 FY2022 financials; identifies material weakness in internal controls
--------------------------------------------------------------------------------

- Net loss for Q1 (June 30, 2022) decreased ~$90K to ~$3.889M; Q2 (Sept 30, 2022) decreased ~$223K to ~$3.856M.
- Errors: incorrect foreign currency translation on mark-to-market contract and omitted debt issuance costs in loan interest computation.
- Material weakness in internal control over financial reporting identified; disclosure controls ineffective as of June 30 and Sept 30, 2022.
- Q3 10-Q for period ended Dec 31, 2022 expected to be delayed beyond Feb 21, 2023 extended deadline; no impact on sales, gross profit, or cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323000236/0001079973-23-000236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323000236/nmra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-000236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer